Scopus BioPharma soars on FDA approval
Scopus BioPharma soars on FDA approval At one stage in yesterday's session, Scopus Biopharma's share price was up 100%. It closed up nearly 80%. Drug company Scopus BioPharma Inc. (Nasdaq: SCPS), has reported that the US Food and Drug Administration (FDA) has approved the start of a clinical trial for the company's RNA cancer therapy (CpG-STAT3siRNA), developed in cooperation with the City of Hope hospital in California. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope. At one stage in yesterday's session, Scopus Biopharma's share price was up 100%. I...
Source: globes.co.il